About Kazia Therapeutics
Kazia Therapeutics ADR (ASX:KZA), (NASDAQ:KZIA) is an innovative biotechnology company focused on the development of novel treatments for cancer. Traded on the NASDAQ under the symbol KZIA, the company's portfolio includes projects aimed at addressing some of the most challenging forms of the disease, such as glioblastoma, the most common and aggressive form of brain cancer. Kazia's primary objective is to advance these treatments through clinical trials with the goal of improving patient outcomes and providing new hope to individuals and families affected by cancer. Through collaboration with leading cancer research institutions and a dedication to scientific excellence, Kazia strives to translate cutting-edge research into therapies that can make a real difference in the fight against cancer.
Snapshot
Operations
Products and/or services of Kazia Therapeutics
- Paxalisib, a PI3K inhibitor designed for treating glioblastoma, a form of brain cancer.
- EVT801, an anti-cancer compound targeting VEGFR3 for various solid tumors.
- Collaboration on using paxalisib in combination therapies for enhanced treatment efficacy in brain cancer.
- Research partnership focused on developing targeted therapies for pediatric brain cancers.
- Initiatives on improving drug delivery systems for better penetration of therapeutics into the brain.
- Investigation into novel biomarkers for more precise treatment targeting in oncology
Kazia Therapeutics executive team
- Dr. John Edwin Friend II, M.D.Chief Executive Officer
- Mr. Jeffrey BonacordaVP of Finance & Controller
- Ms. Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAICCompany Secretary